UBS Group’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $458K | Buy |
48,797
+10,159
| +26% | +$96.2K | ﹤0.01% | 6289 |
|
|
2026
Q1 | $363K | Sell |
38,638
-12,571
| -25% | -$106K | ﹤0.01% | 6299 |
|
|
2025
Q4 | $417K | Sell |
51,209
-8,287
| -14% | -$102K | ﹤0.01% | 6190 |
|
|
2025
Q3 | $753K | Sell |
59,496
-32,347
| -35% | -$308K | ﹤0.01% | 5789 |
|
|
2025
Q2 | $634K | Buy |
91,843
+999
| +1% | +$7.26K | ﹤0.01% | 5821 |
|
|
2025
Q1 | $482K | Buy |
90,844
+1,467
| +2% | +$12.9K | ﹤0.01% | 5878 |
|
|
2024
Q4 | $1.05M | Buy |
89,377
+65,162
| +269% | +$1.09M | ﹤0.01% | 5256 |
|
|
2024
Q3 | $500K | Buy |
24,215
+2,566
| +12% | +$131K | ﹤0.01% | 5229 |
|
|
2024
Q2 | $980K | Buy |
21,649
+6,184
| +40% | +$260K | ﹤0.01% | 4442 |
|
|
2024
Q1 | $607K | Buy |
15,465
+15,144
| +4,718% | +$373K | ﹤0.01% | 5036 |
|
|
2023
Q4 | $1.94K | Sell |
321
-861
| -73% | -$4.62K | ﹤0.01% | 8195 |
|
|
2023
Q3 | $7.97K | Buy |
1,182
+879
| +290% | +$6.08K | ﹤0.01% | 7202 |
|
|
2023
Q2 | $2.38K | Sell |
303
-4,541
| -94% | -$40.8K | ﹤0.01% | 7760 |
|
|
2023
Q1 | $35.2K | Buy |
4,844
+3,845
| +385% | +$16.8K | ﹤0.01% | 6685 |
|
|
2022
Q4 | $3.3K | Sell |
999
-418
| -29% | -$1.61K | ﹤0.01% | 9532 |
|
|
2022
Q3 | $7K | Buy |
1,417
+1,352
| +2,080% | +$9.53K | ﹤0.01% | 8854 |
|
|
2022
Q2 | $0 | Sell |
65
-648
| -91% | -$6.26K | ﹤0.01% | 10389 |
|
|
2022
Q1 | $11K | Sell |
713
-573
| -45% | -$7.59K | ﹤0.01% | 8288 |
|
|
2021
Q4 | $24K | Buy |
1,286
+929
| +260% | +$25.2K | ﹤0.01% | 7623 |
|
|
2021
Q3 | $12K | Sell |
357
-237
| -40% | -$9.35K | ﹤0.01% | 7746 |
|
|
2021
Q2 | $33K | Sell |
594
-62
| -9% | -$3.44K | ﹤0.01% | 6824 |
|
|
2021
Q1 | $39K | Buy |
656
+541
| +470% | +$35.6K | ﹤0.01% | 6781 |
|
|
2020
Q4 | $4K | Sell |
115
-18
| -14% | -$673 | ﹤0.01% | 7900 |
|
|
2020
Q3 | $7K | Sell |
133
-5,670
| -98% | -$1.03M | ﹤0.01% | 7104 |
|
|
2020
Q2 | $1.46M | Buy |
5,803
+4,445
| +327% | +$898K | ﹤0.01% | 3168 |
|
|
2020
Q1 | $214K | Sell |
1,358
-1,547
| -53% | -$262K | ﹤0.01% | 4669 |
|
|
2019
Q4 | $476K | Buy |
2,905
+1,204
| +71% | +$178K | ﹤0.01% | 4881 |
|
|
2019
Q3 | $248K | Buy |
1,701
+1,231
| +262% | +$214K | ﹤0.01% | 5076 |
|
|
2019
Q2 | $98K | Buy |
470
+46
| +11% | +$9.85K | ﹤0.01% | 5385 |
|
|
2019
Q1 | $89K | Buy |
424
+101
| +31% | +$22.3K | ﹤0.01% | 5147 |
|
|
2018
Q4 | $57K | Buy |
323
+181
| +127% | +$36.1K | ﹤0.01% | 5976 |
|
|
2018
Q3 | $33K | Sell |
142
-1
| -0.7% | -$162 | ﹤0.01% | 6461 |
|
|
2018
Q2 | $22K | Buy |
143
+56
| +64% | +$10.2K | ﹤0.01% | 6631 |
|
|
2018
Q1 | $16K | Buy |
87
+54
| +164% | +$12.1K | ﹤0.01% | 6556 |
|
|
2017
Q4 | $7K | Sell |
33
-75
| -69% | -$16.1K | ﹤0.01% | 7218 |
|
|
2017
Q3 | $23K | Buy |
108
+44
| +69% | +$8.61K | ﹤0.01% | 6342 |
|
|
2017
Q2 | $12K | Buy |
64
+26
| +68% | +$5.1K | ﹤0.01% | 6638 |
|
|
2017
Q1 | $9K | Buy |
38
+5
| +15% | +$1.23K | ﹤0.01% | 6666 |
|
|
2016
Q4 | $8K | Sell |
33
-41
| -55% | -$9.4K | ﹤0.01% | 7027 |
|
|
2016
Q3 | $15K | Hold |
74
| – | – | ﹤0.01% | 6512 |
|
|
2016
Q2 | $7K | Sell |
74
-21
| -22% | -$1.65K | ﹤0.01% | 6962 |
|
|
2016
Q1 | $5K | Sell |
95
-19
| -17% | -$838 | ﹤0.01% | 6995 |
|
|
2015
Q4 | $6K | Sell |
114
-19
| -14% | -$968 | ﹤0.01% | 7594 |
|
|
2015
Q3 | $7K | Buy |
133
+67
| +102% | +$4.46K | ﹤0.01% | 7482 |
|
|
2015
Q2 | $6K | Buy |
+66
| New | +$6.64K | ﹤0.01% | 7774 |
|
Other funds holding CRBP
CAM
O
JHC
PM
SCM
ACM
UBS Group's CRBP Position: Q2 2026 in Review
UBS Group increased its Corbus Pharmaceuticals (CRBP) stake by 26% in Q2 2026, buying an estimated $96.2K and bringing the position to 48,797 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #6289.
UBS Group first reported a position in CRBP in Q2 2015 and has held it in 45 quarters since. The position peaked at $1.46M in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.
- UBS Group held 48,797 shares of Corbus Pharmaceuticals worth $458K as of Q2 2026.
- UBS Group bought 10,159 Corbus Pharmaceuticals shares in Q2 2026, an estimated $96.2K.
- Corbus Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6289 holding.
- UBS Group first reported a position in Corbus Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
- UBS Group's Corbus Pharmaceuticals position peaked at $1.46M in Q2 2020.
- 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.